Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828059 | 0.87 | AKR1C3 (0.65) | AKR1C3AKR1C2AKR1C1PTGS1ACHE | |
| SCHEMBL27524318 | 0.81 | ACHE (0.55) | FDPSAKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL8092960 | 0.80 | AKR1C3 (0.60) | AKR1C3AKR1C2AKR1C1PTGS1ACHE | |
| SCHEMBL6612965 | 0.79 | AKR1C3 (0.55) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL6023746 | 0.79 | AKR1C3 (0.56) | AKR1C3AKR1C2AKR1C1PTGS1ACHE | |
| SCHEMBL11315398 | 0.79 | LMNA (0.53) | AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL2495059 | 0.78 | AKR1C3 (0.58) | AKR1C3AKR1C2AKR1C1PTGS1ACHE | |
| SCHEMBL18888185 | 0.78 | FDPS (0.55) | FDPSACHEKDM4E | |
| SCHEMBL298386 | 0.78 | TSHR (0.67) | AKR1C3AKR1C2AKR1C1PTGS1ACHE | |
| SCHEMBL26093138 | 0.78 | AKR1C3 (0.61) | AKR1C3AKR1C2AKR1C1PTGS1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | FDPS 2813/4885AKR1C3 1058/4885AKR1C2 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.